• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Zymergen Inc. (Amendment)

    2/11/22 3:56:22 PM ET
    $ZY
    Industrial Specialties
    Industrials
    Get the next $ZY alert in real time by email
    SC 13G/A 1 efc22-186_sc13ga.htm

     
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     

     
    SCHEDULE 13G
     
    Under the Securities Exchange Act of 1934
    (Amendment No._1)*
     

     
    Zymergen Inc.
    (Name of Issuer)
     
    Common Stock, $0.001 par value per share
    (Title of Class of Securities)
     
    98985X100
    (CUSIP Number)
     
    December 31, 2021
    (Date of Event Which Requires Filing of this Statement)
     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
     
    ☐  Rule 13d-1(b)
     
    ☒ Rule 13d-1(c)
     
    ☐  Rule 13d-1(d)

    *
    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     

     

    CUSIP No. 98985X100
    SCHEDULE 13G
    Page 2 of 5 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
     GIC Private Limited
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
     Republic of Singapore
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
     4,106,390
     
     
     
     
    6
    SHARED VOTING POWER
     
     
     972,512
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
     4,106,390
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
     972,512
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
     5,078,902
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
     4.96% (1)
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
     CO
     
     
     
     


    (1)
    Based on 102,400,795 Class A Shares outstanding as of October 22, 2021, according to the Form 10-Q filed by the Issuer with the Securities and Exchange Commission on November 15, 2021.
     

    CUSIP No. 98985X100
    SCHEDULE 13G
    Page 3 of 5 Pages

     
    Item 1(a).
    Name of Issuer:
     
    Zymergen, Inc. (the “Issuer”)
     
    Item 1(b).
    Address of Issuer’s Principal Executive Offices:
     
    5980 Horton Street, Suite 105
    Emeryville, California 94608
     
    Item 2(a).
    Name of Person Filing:
     
    GIC Private Limited (“GIC”)

    Item 2(b).
    Address of Principal Business Office or, if None, Residence:
     
    168 Robinson Road
    #37-01 Capital Tower
    Singapore 068912

    Item 2(c).
    Citizenship:
     
    Republic of Singapore

    Item 2(d).
    Title of Class of Securities:
     
    Common Stock, $0.001 par value per share
     
    Item 2(e).
    CUSIP Number:
     
    98985X100
     
    Item 3.
    If this Statement is Filed Pursuant to 240.13d-1(b), or 240.13d-2(b) or (c), Check Whether the Person Filing is a:
     
    Not applicable.
     
    Item 4.
    Ownership.
     
    (a - c)  The aggregate number of securities and percentage of the class of securities of the Issuer beneficially owned by each Reporting Person named in Item 2(a), as well as the number of securities as to which such person is deemed to have sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, shared power to dispose or direct the disposition, is set forth in the following tables:

     
    Reporting Person
    Amount Beneficially Owned (1)
    Percent of Class (2)
    GIC Private Limited
    5,078,902
    4.96%
         
    Reporting Person
    Voting Power
    Dispositive Power
     
    Sole (1)
    Shared (1)
    Sole (1)
    Shared (1)
    GIC Private Limited
    4,106,390
    972,512
    4,106,390
    972,512

     
    (1) GIC is a fund manager and only has 2 clients – the Government of Singapore (“GoS”) and the Monetary Authority of Singapore (“MAS”).  Under the investment management agreement with GoS, GIC has been given the sole discretion to exercise the voting rights attached to, and the disposition of, any shares managed on behalf of GoS.  As such, GIC has the sole power to vote and power to dispose of the 4,106,390 securities beneficially owned by it.  GIC shares power to vote and dispose of 972,512 securities beneficially owned by it with MAS.

    GIC is wholly-owned by GoS and was set up with the sole purpose of managing Singapore’s foreign reserves. The GoS disclaims beneficial ownership of such shares.

    (2) Based on 102,400,795 Class A Shares outstanding as of October 22, 2021, according to the Form 10-Q filed by the Issuer with the Securities and Exchange Commission on November 15, 2021.

    CUSIP No. 98985X100
    SCHEDULE 13G
    Page 4 of 5 Pages

     
    Item 5.
    Ownership of Five Percent or Less of Class.
     
    If this statement is being filed to report the fact that as of the date hereof GIC has ceased to be the beneficial owner of more than 5 percent of the Common Stock, check the following [X]
     
    Item 6.
    Ownership of More Than Five Percent on Behalf of Another Person.
     
    Not applicable.
     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.
     
    Not applicable.
     
    Item 8.
    Identification and Classification of Members of the Group.
     
    Not applicable.
     
    Item 9.
    Notice of Dissolution of Group.
     
    Not applicable.
     
    Item 10.
    Certifications.
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.
     


    CUSIP No. 98985X100
    SCHEDULE 13G
    Page 5 of 5 Pages
     
     
    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct as dated.
     
      GIC PRIVATE LIMITED  
           

    By:
    /s/ Celine Loh Sze Ling  
        Name: Celine Loh Sze Ling  
        Title:   Senior Vice President  
        Date:   February 11, 2021  
           
      By: /s/ Diane Liang Weishan  
        Name: Diane Liang Weishan  
        Title:   Senior Vice President  
        Date:   February 11, 2021  



    Get the next $ZY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ZY

    DatePrice TargetRatingAnalyst
    3/2/2022Market Perform
    Cowen
    1/12/2022$6.50Reduce → Hold
    HSBC Securities
    10/15/2021Market Perform
    Cowen
    9/27/2021$12.00Neutral → Underweight
    JP Morgan
    8/31/2021$56.00 → $13.00Buy → Neutral
    UBS
    8/4/2021$43.00 → $7.00Buy → Underperform
    BofA Securities
    8/4/2021Outperform → Market Perform
    Cowen & Co.
    8/4/2021$55.00 → $12.00Buy → Neutral
    Goldman Sachs
    More analyst ratings

    $ZY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Svf Excalibur (Cayman) Ltd disposed of 26,614,219 shares

    4 - Zymergen Inc. (0001645842) (Issuer)

    10/21/22 4:30:20 PM ET
    $ZY
    Industrial Specialties
    Industrials

    SEC Form 4: Flatley Jay T returned 144,789 shares to the company, closing all direct ownership in the company

    4 - Zymergen Inc. (0001645842) (Issuer)

    10/19/22 8:17:59 PM ET
    $ZY
    Industrial Specialties
    Industrials

    SEC Form 4: Chu Steven returned 50,000 shares to the company, closing all direct ownership in the company

    4 - Zymergen Inc. (0001645842) (Issuer)

    10/19/22 8:15:58 PM ET
    $ZY
    Industrial Specialties
    Industrials

    $ZY
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ginkgo Bioworks Completes Acquisition of Zymergen

    BOSTON and EMERYVILLE, Calif., Oct. 19, 2022 /PRNewswire/ -- Today, Ginkgo Bioworks (NYSE:DNA), the leading horizontal platform for cell programming, and Zymergen (NASDAQ:ZY) announced that Ginkgo has completed its previously announced acquisition of Zymergen. The acquisition is expected to significantly enhance Ginkgo's platform by integrating strong automation and software capabilities as well as a wealth of experience across diverse biological engineering approaches. "Today marks an important step in our long-term growth as we complete the Zymergen acquisition and welcome t

    10/19/22 9:08:00 AM ET
    $DNA
    $ZY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Industrial Specialties
    Industrials

    Ginkgo to Acquire Zymergen

    Acquisition is expected to accelerate the development of Ginkgo's innovative horizontal synthetic biology platformExpect integration of Zymergen's complementary automation, software, and data science tools as well as biological assets to significantly enhance the capacity, capabilities, and efficiency of Ginkgo's platform for its diverse customer base and enable new growth opportunities across many end marketsZymergen's core technical team is expected to help fill significant planned hiring by Ginkgo across its cell engineering, automation, digital technology, and data teams, accelerating scaling efforts while minimizing incremental run-rate operating expenses following integration of the ac

    7/25/22 7:01:00 AM ET
    $DNA
    $ZY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Industrial Specialties
    Industrials

    Zymergen Expands Agreement with Octant to Scale Next-Generation Drug Discovery Platform

    EMERYVILLE, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. ("Zymergen" or the "Company") today announced it has expanded its agreement with Octant to further scale their next-generation platform to develop breakthrough medicines. In May, Octant purchased five Reconfigurable Automation Carts, or RACs, to improve the throughput, efficiency, and reliability of operations for its existing platform. Octant has now more than doubled its initial investment through the purchase of an additional six RAC units, vastly increasing the system's throughput, capabilities, and ability to run complex workflows. "We've been extremely pleased with the performance of our current RAC System and are l

    7/14/22 4:56:39 PM ET
    $ZY
    Industrial Specialties
    Industrials

    $ZY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cowen resumed coverage on Zymergen

    Cowen resumed coverage of Zymergen with a rating of Market Perform

    3/2/22 8:44:04 AM ET
    $ZY
    Industrial Specialties
    Industrials

    Zymergen upgraded by HSBC Securities with a new price target

    HSBC Securities upgraded Zymergen from Reduce to Hold and set a new price target of $6.50

    1/12/22 7:08:41 AM ET
    $ZY
    Industrial Specialties
    Industrials

    Cowen resumed coverage on Zymergen

    Cowen resumed coverage of Zymergen with a rating of Market Perform

    10/15/21 7:34:23 AM ET
    $ZY
    Industrial Specialties
    Industrials

    $ZY
    SEC Filings

    View All

    SEC Form 15-12G filed by Zymergen Inc.

    15-12G - Zymergen Inc. (0001645842) (Filer)

    10/31/22 4:47:58 PM ET
    $ZY
    Industrial Specialties
    Industrials

    SEC Form EFFECT filed by Zymergen Inc.

    EFFECT - Zymergen Inc. (0001645842) (Filer)

    10/26/22 12:15:12 AM ET
    $ZY
    Industrial Specialties
    Industrials

    SEC Form POS AM filed by Zymergen Inc.

    POS AM - Zymergen Inc. (0001645842) (Filer)

    10/19/22 12:36:00 PM ET
    $ZY
    Industrial Specialties
    Industrials

    $ZY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Zymergen Inc. (Amendment)

    SC 13G/A - Zymergen Inc. (0001645842) (Subject)

    10/21/22 4:31:00 PM ET
    $ZY
    Industrial Specialties
    Industrials

    SEC Form SC 13G filed by Zymergen Inc.

    SC 13G - Zymergen Inc. (0001645842) (Subject)

    2/14/22 3:22:50 PM ET
    $ZY
    Industrial Specialties
    Industrials

    SEC Form SC 13G filed by Zymergen Inc.

    SC 13G - Zymergen Inc. (0001645842) (Subject)

    2/14/22 9:36:54 AM ET
    $ZY
    Industrial Specialties
    Industrials

    $ZY
    Financials

    Live finance-specific insights

    View All

    Ginkgo to Acquire Zymergen

    Acquisition is expected to accelerate the development of Ginkgo's innovative horizontal synthetic biology platformExpect integration of Zymergen's complementary automation, software, and data science tools as well as biological assets to significantly enhance the capacity, capabilities, and efficiency of Ginkgo's platform for its diverse customer base and enable new growth opportunities across many end marketsZymergen's core technical team is expected to help fill significant planned hiring by Ginkgo across its cell engineering, automation, digital technology, and data teams, accelerating scaling efforts while minimizing incremental run-rate operating expenses following integration of the ac

    7/25/22 7:01:00 AM ET
    $DNA
    $ZY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Industrial Specialties
    Industrials

    Zymergen Reports Preliminary First Quarter 2022 Financial Results

    EMERYVILLE, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Biotechnology company Zymergen Inc. ("Zymergen" or the "Company"), today reported preliminary financial results for the first quarter ended March 31, 2022. "Our mission at Zymergen is to partner with nature to make better products, a better way, for a better world. One of the key transformations we have made is to create a nimble, disciplined product development process," said Zymergen's interim CEO, Jay Flatley. "We now have the infrastructure to support great execution and the delivery of products across our three businesses of Advanced Materials, Drug Discovery and Automation." Preliminary First Quarter 2022 Financial ResultsTotal r

    5/12/22 4:05:00 PM ET
    $ZY
    Industrial Specialties
    Industrials

    Zymergen to Report Preliminary First Quarter 2022 Financial Results on May 12, 2022

    EMERYVILLE, Calif., April 13, 2022 (GLOBE NEWSWIRE) -- Zymergen Inc. ("Zymergen" or the "Company") today announced it will report preliminary financial results for the first quarter 2022 after market close on Thursday, May 12, 2022. The company's management will host a conference call beginning at 1:30 PM Pacific Time / 4:30 PM Eastern Time to discuss its results. A webcast of the conference call can be accessed at https://investors.zymergen.com/. About Zymergen Zymergen is a biotech company that designs and produces molecules, microbes and materials for diverse end markets. We partner with nature to make better products, a better way, for a better world. Investor Contactinvest

    4/13/22 4:05:00 PM ET
    $ZY
    Industrial Specialties
    Industrials